Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.

ABSTRACT:

Background

Development of an effective vaccine against the pathogenic blood-stage infection of human malaria has proved challenging, and no candidate vaccine has affected blood-stage parasitemia following controlled human malaria infection (CHMI) with blood-stage Plasmodium falciparum.

Methods

We undertook a phase I/IIa clinical trial in healthy adults in the United Kingdom of the RH5.1 recombinant protein vaccine, targeting the P. falciparum reticulocyte-binding protein homolog 5 (RH5), formulated in AS01_B adjuvant. We assessed safety, immunogenicity, and efficacy against blood-stage CHMI. Trial registered at ClinicalTrials.gov, NCT02927145.

Findings

The RH5.1/AS01_B formulation was administered using a range of RH5.1 protein vaccin

SUBMITTER: Minassian AM 

PROVIDER: S-EPMC8240500 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature